Tarsus Pharmaceuticals
Manufacturing · California, United States · 50 Employees
Founded in 2017, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases. The company's lead product is a topical ophthalmic that targets an underlying cause of blepharitis. Tarsus is headquartered in Irvine, California.Read More
Tarsus Pharmaceuticals Org Chart
Tarsus Pharmaceuticals Company Metrics
Funding
Funding DateFeb 03, 2022
RoundDebt
Amount$175M
Investors
Funding DateJan 09, 2020
RoundSeries B
Amount$60M
InvestorsAPERTURE Venture Partners, Frazier Healthcare Partners, Visionary Ventures, Flying L Partners, Horowitz Group, Vivo Capital
Funding DateMar 01, 2018
RoundSeries A
Amount-
Investors
See More
$235M
Total Funding Amount
$175M
Most Recent Funding Amount
3
Number of Funding Rounds
Tarsus Pharmaceuticals Tech Stack
Tarsus Pharmaceuticals News & Media
Tarsus to Present at Upcoming Investor Conferences
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate at the following conferences:Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months
Quite a few insiders have dramatically grown their holdings in Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) over the...Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CFO Leonard M. Greenstein Sells ... - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Rating) CFO Leonard M. Greenstein sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $14.56, for a total transaction of $72,800.00. Following the completion of the transaction, the chief financial officer now owns 39,289 shares in the company, valued at $572,047.84. The transaction was disclosed in a filing with the Securities & ExchangeTarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a
Read more news
Frequently Asked Questions regarding Tarsus Pharmaceuticals
Founded in 2017, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases. The company's lead product is a topical ophthalmic that targets an underlying cause of blepharitis. Tarsus is headquartered in Irvine, California.... Read More